VYNDAQEL 20 MG
TAFAMIDIS MEGLUMINE : 20 MG · DIN 02495732 · PFIZER CANADA ULC
Health Canada status: MARKETED
What is VYNDAQEL?
VYNDAQEL 20 MG contains TAFAMIDIS MEGLUMINE : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02495732, held by PFIZER CANADA ULC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 07-Apr-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is VYNDAQEL used for?
Treatment of adult patients with cardiomyopathy due to transthyretin-mediated amyloidosis (ATTR-CM), wild-type or hereditary, to reduce cardiovascular mortality and CV-related hospitalization.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02495732 |
|---|---|
| Brand name | VYNDAQEL |
| Generic / active ingredient | TAFAMIDIS MEGLUMINE : 20 MG |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 20 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N07XX08 TAFAMIDIS |
| AHFS class | 38:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 07-Apr-2020 |
How is it administered?
Recommended dose: 80 mg (four 20 mg capsules) orally once daily. May be reduced to 20 mg if not tolerated. Swallow whole; do not crush or cut. May be taken with or without food.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at room temperature 15°C to 25°C.
How is it supplied?
120 capsules (one month supply) supplied in 4 intermediary cartons. Each intermediary carton contains 3 blister cards, with 10 capsules each.
Contraindications
Hypersensitivity to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
Warnings and precautions
Not recommended in organ transplant patients. Animal studies show developmental toxicity. Potential for serious adverse reactions in breastfed infants; should not be used by nursing women.
What can be used instead?
Other Canadian products sharing ATC code N07XX08 TAFAMIDIS. 2 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| VYNDAMAX | 61 MG | Capsule | PFIZER CANADA ULC | MARKETED | DIN 02517841 |
Who else supplies TAFAMIDIS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TAFAMIDIS appears in 23 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.